Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1326110 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $6.97Day −0.29%Mkt cap $7.3B1Y +163.0%Off 52W high −43.9%Vol (1Y) 106.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,343 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.8% of sh out |
| Days to cover11.9d |
| 13F net flow (QoQ)−1.15% |
| Top-10 13F concentration62.9% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$141.0M |
| Earnings (TTM)-$854.5M |
| Net margin−310.2% |
| Sales growth 3Y678.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+252.0% |
| 1Y+163.0% |
| 3Y+204.4% |
| 5Y−39.3% |
| Since incept. (ann.)−24.9% |
Total return through 2026-07-28 · series begins 2021-03-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)106.0% |
| Ann. volatility (3Y)110.1% |
| Sharpe (1Y)1.42 |
| Sharpe (3Y)0.86 |
| Max drawdown (1Y)−42.3% |
| Max drawdown (3Y)−79.3% |
| Beta (3Y vs SPY)0.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 26.3M | $202M | 2.52% | +2.9% |
| STATE STREET CORP | 17.7M | $136M | 1.69% | +7.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 16.3M | $125M | 1.56% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 15.1M | $116M | 1.44% | new |
| D. E. Shaw & Co., Inc. | 12.6M | $96M | 1.20% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 8.0M | $62M | 0.77% | +1.4% |
| TWO SIGMA INVESTMENTS, LP | 4.4M | $34M | 0.42% | −7.0% |
| MORGAN STANLEY | 4.0M | $31M | 0.38% | −21.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.62 | — | $44.2M | +167.6% |
| 2025-12-31 | 2026-02-23 | — | — | $38.3M | +407.0% |
| 2025-09-30 | 2025-11-05 | −$0.07 | — | $32.1M | +425.1% |
| 2025-06-30 | 2025-08-05 | −$0.10 | — | $26.4M | +2423.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
